Business Wire

Milrem Developing a Robotic Warfare System to Keep Soldiers Safe in Battle

22.3.2017 12:00 | Business Wire

Del

Defense solutions provider Milrem is developing smart unmanned ground vehicles with concepts of how to use them on the modern battlefield as adaptive systems to minimize dangerous risks to warfighters. Milrem will launch joint product efforts with KONGSBERG and QinetiQ North America this week.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170322005353/en/

Milrem's fully modular unmanned ground vehicle THeMIS equipped with KONGSBERG PROTECTOR Remote Weapo ...

Milrem's fully modular unmanned ground vehicle THeMIS equipped with KONGSBERG PROTECTOR Remote Weapon Station (Photo: Business Wire)

Milrem has developed the first fully modular unmanned ground vehicle with a hybrid diesel-electric drive, the THeMIS. This open architecture system may be configured mission-specific as required to be used in various combat roles.

With a 1:1 high payload of 750 kg / 1650 lbs., THeMIS may also be equipped with a remote weapon station with embedded target detection and acquisition systems to provide fire support.

A remotely operated robotic fire support and force protection system has been developed with leading military innovators KONGSBERG and QinetiQ North America (QNA) and is being introduced at the Ground Robotics Capabilities Exhibition & Conference 2017 (GRCCE) this week. This joint effort features the THeMIS unmanned ground vehicle, the PROTECTOR Remote Weapon Station, and QNA’s UGV control systems.

“This is a great opportunity to collaborate with such an esteemed company as KONGSBERG and continue our cooperation with QNA. Integration of this remote weapon station is another example of how easily the THeMIS can be configured for different applications. These various applications form a system of robotic warfare capabilities” explained Kuldar Vaarsi, CEO of Milrem.

Last October the companies introduced the Titan UGV for dismounted troop support that features the THeMIS UGV with QNA's UGV control technology - the Tactical Robot Controller (TRC) and Robotic Appliqué Kit (RAK). This vehicle will also be displayed at GRCCE.

In parallel, Milrem is developing technologies for military forces to enable how unmanned ground systems may be used in combat as an efficient and powerful manned-unmanned teaming system that reduces battlefield risks to warfighters.

The end results of this program, known as Digital Infantry Battlefield Solution (DIBS) will result in recommendations for military doctrine in order to effectively use the capability of robotic systems.

To see the THeMIS in combat, please visit https://www.youtube.com/watch?v=DfqGuFYKSoE and https://www.youtube.com/watch?v=nTdRVkJ-YAU

About Milrem

Milrem is an Estonian technology solutions provider. The company’s key business areas include the research and development of unmanned vehicles and life cycle management for heavy military vehicles.

Contact information

Milrem
Gert Hankewitz, +372 56644416
Marketing Director
gert.hankewitz@milrem.ee

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom